{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:41:36Z","timestamp":1787240496542,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.clinthera.2011.01.008","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T09:06:24Z","timestamp":1298538384000},"page":"2386-2397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials"],"prefix":"10.1016","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct00102440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00174915","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00430248","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robert L.","family":"Wortmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.01.008_bib1","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2011.01.008_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.01.008_bib3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.clinthera.2011.01.008_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/art.1780080455","article-title":"The effect of allopurinol (HPP) in the treatment of gout","volume":"8","author":"Houpt","year":"1965","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.01.008_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.16.4.425","article-title":"Evaluation of uricosuric agents in chronic gout","volume":"16","author":"Ogryzlo","year":"1957","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2011.01.008_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.26.2.136","article-title":"Allopurinol in the treatment of uraemic patients with gout","volume":"26","author":"Wilson","year":"1967","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2011.01.008_bib7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/art.1780010606","article-title":"Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects","volume":"1","author":"Yu","year":"1958","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.01.008_bib8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0002-9343(64)90131-7","article-title":"Effect of allopurinol (4-hydroxypyrazolo-(3,4-D)pyrimidine) on serum and urinary uric acid in primary and secondary gout","volume":"37","author":"Yue","year":"1964","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2011.01.008_bib9","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.01.008_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.01.008_bib11","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2011.01.008_bib12","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: Present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2011.01.008_bib13","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2011.01.008_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","article-title":"Prophylactic colchicine therapy of intercritical gout","volume":"17","author":"Paulus","year":"1974","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.01.008_bib15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2011.01.008_bib16","series-title":"Uloric [package insert]","year":"2009"},{"key":"10.1016\/j.clinthera.2011.01.008_bib17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2011.01.008_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-Yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2011.01.008_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.01.008_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.clinthera.2011.01.008_bib21","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/00003246-199310000-00016","article-title":"Predictability of creatinine clearance estimates in critically ill patients","volume":"21","author":"Robert","year":"1993","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2011.01.008_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/ard.33.4.313","article-title":"Factors affecting urate solubility in vitro","volume":"33","author":"Kippen","year":"1974","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2011.01.008_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2011.01.008_bib25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2011.01.008_bib26","first-page":"S435","article-title":"Epidemiology of hyperuricemia and gout","volume":"11","author":"Luk","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2011.01.008_bib27","first-page":"31","article-title":"Effect of anturane on serum uric acid and cholesterol in gout: A long-term study","volume":"8","author":"Kuzell","year":"1964","journal-title":"Acta Rheumatol Scand Suppl"},{"key":"10.1016\/j.clinthera.2011.01.008_bib28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3899\/jrheum.080938","article-title":"Serum urate during acute gout","volume":"36","author":"Schlesinger","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2011.01.008_bib29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","article-title":"Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: A prospective study","volume":"55","author":"Perez-Ruiz","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.01.008_bib30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1136\/bmj.325.7371.980","article-title":"Treating acute gouty arthritis with selective COX 2 inhibitors","volume":"325","author":"Fam","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2011.01.008_bib31","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1182\/blood.V91.5.1769","article-title":"Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes","volume":"91","author":"Pouliot","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.01.008_bib32","first-page":"261","article-title":"Gout: A review of its aetiology and treatment","volume":"10","author":"Li","year":"2004","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.clinthera.2011.01.008_bib33","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/art.21238","article-title":"Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation","volume":"52","author":"Liu-Bryan","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2011.01.008_bib34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2011.01.008_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.01.008_bib36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(98)00323-4","article-title":"Effective management of gout: An analogy","volume":"105","author":"Wortmann","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2011.01.008_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2011.01.008_bib38","series-title":"Prevacid [package insert]","year":"2008"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811000099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811000099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:48Z","timestamp":1758962928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":37,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0149291811000099"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.01.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}